Aine Cryts
Aine Cryts is a freelancer based in Boston. She is a frequent contributor to Managed Healthcare Executive on topics such as diabetes, oncology, hospital admissions and readmissions, senior patients, and health policy.
CAR T-cell therapies in treating lymphoma: Pros and cons
Catherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Three things health execs need to know about CAR T-cell therapy
Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
Ovarian cancer could be next application for CAR T-cell therapy
While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Treating frail elderly patients with multiple myeloma requires different approach
Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.
Patient experience with immunotherapy: 4 things health execs need to know
CAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.
Unique payer-provider cancer treatment partnerships
Unique partnerships between payers and providers focus on keeping patients out of the hospital and on the road to remission.
Managing cancer treatment side effects: What payers should know
Moffitt Cancer Center expert shares her thinking on managing chemotherapy-related side effects.
Four new treatments for acute myeloid leukemia to watch
Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.
Four new treatments for acute myeloid leukemia to watch
Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.
This is why you should be excited for upcoming cancer research
Acute myeloid leukemia experts share promising new developments on the oncology horizon.

Poll

View Results